-
Something wrong with this record ?
Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance
L. Heczko, V. Liška, O. Vyčítal, O. Fiala, S. Šůsová, V. Hlaváč, P. Souček
Language English Country England, Great Britain
Document type Journal Article
Grant support
FNPl 00669806
Ministerstvo Zdravotnictví Ceské Republiky
23-05609S
Grantová Agentura České Republiky
NV19-08-00113
Agentura Pro Zdravotnický Výzkum České Republiky
NLK
BioMedCentral
from 2003-12-01
BioMedCentral Open Access
from 2003
Directory of Open Access Journals
from 2003
Free Medical Journals
from 2003
PubMed Central
from 2003
ProQuest Central
from 2003-11-01
Open Access Digital Library
from 2003-01-01
Open Access Digital Library
from 2003-01-01
Medline Complete (EBSCOhost)
from 2003-11-01
Health & Medicine (ProQuest)
from 2003-11-01
ROAD: Directory of Open Access Scholarly Resources
from 2003
Springer Nature OA/Free Journals
from 2003-12-01
- MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Adult MeSH
- F-Box-WD Repeat-Containing Protein 7 genetics MeSH
- Pharmacogenetics methods MeSH
- Fluorouracil therapeutic use MeSH
- Class I Phosphatidylinositol 3-Kinases MeSH
- Colorectal Neoplasms * genetics drug therapy pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation genetics MeSH
- Biomarkers, Tumor genetics MeSH
- Tumor Suppressor Protein p53 genetics MeSH
- Prognosis MeSH
- Adenomatous Polyposis Coli Protein genetics MeSH
- Proto-Oncogene Proteins p21(ras) genetics MeSH
- Aged MeSH
- High-Throughput Nucleotide Sequencing MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Colorectal cancer is still the second leading cause of cancer-related deaths and thus biomarkers allowing prediction of the resistance of patients to therapy and estimating their prognosis are needed. We designed a panel of 558 genes with pharmacogenomics records related to 5-fluorouracil resistance, genes important for sensitivity to other frequently used drugs, major oncodrivers, and actionable genes. We performed a target enrichment sequencing of DNA from tumors and matched blood samples of patients, and compared the results with patient prognosis stratified by systemic adjuvant chemotherapy. RESULTS: The median number of detected variants per tumor sample was 18.5 with 4 classified as having a high predicted functional effect and 14.5 moderate effect. APC, TP53, and KRAS were the most frequent mutated genes (64%, 59%, and 42% of mutated samples, respectively) followed by FAT4 (23%), FBXW7, and PIK3CA (16% for both). Patients with advanced stage III had more frequently APC, TP53, or KRAS mutations than those in stages I or II. KRAS mutation counts followed an increasing trend with grade (G1 < G2 < G3). The response to adjuvant therapy was worse in carriers of frameshift mutations in APC or 12D variant in KRAS, but none of these oncodrivers had prognostic value. Carriage of somatic mutations in any of the genes ABCA13, ANK2, COL7A1, NAV3, or UNC80 had prognostic relevance for worse overall survival (OS) of all patients. In contrast, mutations in FLG, GLI3, or UNC80 were prognostic in the same direction for patients untreated, and mutations in COL6A3, LRP1B, NAV3, RYR1, RYR3, TCHH, or TENM4 for patients treated with adjuvant therapy. The first association was externally validated. From all germline variants with high or moderate predicted functional effects (median 326 per patient), > 5% frequency and positive Manhattan plot based on 3-year RFS, rs72753407 in NFACS, rs34621071 in ERBB4, and rs2444274 in RIF1 were significantly associated with RFS, OS or both. CONCLUSIONS: The present study identified several putative somatic and germline genetic events with prognostic potential for colorectal cancer that should undergo functional characterization.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019709
- 003
- CZ-PrNML
- 005
- 20241024110659.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s40246-024-00644-2 $2 doi
- 035 __
- $a (PubMed)39030589
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Heczko, Lucie $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic
- 245 10
- $a Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance / $c L. Heczko, V. Liška, O. Vyčítal, O. Fiala, S. Šůsová, V. Hlaváč, P. Souček
- 520 9_
- $a BACKGROUND: Colorectal cancer is still the second leading cause of cancer-related deaths and thus biomarkers allowing prediction of the resistance of patients to therapy and estimating their prognosis are needed. We designed a panel of 558 genes with pharmacogenomics records related to 5-fluorouracil resistance, genes important for sensitivity to other frequently used drugs, major oncodrivers, and actionable genes. We performed a target enrichment sequencing of DNA from tumors and matched blood samples of patients, and compared the results with patient prognosis stratified by systemic adjuvant chemotherapy. RESULTS: The median number of detected variants per tumor sample was 18.5 with 4 classified as having a high predicted functional effect and 14.5 moderate effect. APC, TP53, and KRAS were the most frequent mutated genes (64%, 59%, and 42% of mutated samples, respectively) followed by FAT4 (23%), FBXW7, and PIK3CA (16% for both). Patients with advanced stage III had more frequently APC, TP53, or KRAS mutations than those in stages I or II. KRAS mutation counts followed an increasing trend with grade (G1 < G2 < G3). The response to adjuvant therapy was worse in carriers of frameshift mutations in APC or 12D variant in KRAS, but none of these oncodrivers had prognostic value. Carriage of somatic mutations in any of the genes ABCA13, ANK2, COL7A1, NAV3, or UNC80 had prognostic relevance for worse overall survival (OS) of all patients. In contrast, mutations in FLG, GLI3, or UNC80 were prognostic in the same direction for patients untreated, and mutations in COL6A3, LRP1B, NAV3, RYR1, RYR3, TCHH, or TENM4 for patients treated with adjuvant therapy. The first association was externally validated. From all germline variants with high or moderate predicted functional effects (median 326 per patient), > 5% frequency and positive Manhattan plot based on 3-year RFS, rs72753407 in NFACS, rs34621071 in ERBB4, and rs2444274 in RIF1 were significantly associated with RFS, OS or both. CONCLUSIONS: The present study identified several putative somatic and germline genetic events with prognostic potential for colorectal cancer that should undergo functional characterization.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kolorektální nádory $x genetika $x farmakoterapie $x patologie $7 D015179
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mutace $x genetika $7 D009154
- 650 _2
- $a fluoruracil $x terapeutické užití $7 D005472
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a chemorezistence $x genetika $7 D019008
- 650 _2
- $a farmakogenetika $x metody $7 D010597
- 650 _2
- $a protein familiární adenomatózní polypózy $x genetika $7 D025601
- 650 _2
- $a F-Box a WD repetice obsahující protein 7 $x genetika $7 D000073979
- 650 _2
- $a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
- 650 _2
- $a vysoce účinné nukleotidové sekvenování $7 D059014
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 650 _2
- $a fosfatidylinositol-3-kinasy třídy I $7 D058534
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Liška, Václav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic $u Department of Surgery, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Vyčítal, Ondřej $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic $u Department of Surgery, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Fiala, Ondřej $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Šůsová, Simona $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic
- 700 1_
- $a Hlaváč, Viktor $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic. viktor.hlavac@lfp.cuni.cz $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. viktor.hlavac@lfp.cuni.cz $1 https://orcid.org/0000000306950552 $7 xx0270481
- 700 1_
- $a Souček, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 323 00, Czech Republic. pavel.soucek@lfp.cuni.cz $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. pavel.soucek@lfp.cuni.cz $1 https://orcid.org/0000000242946799 $7 xx0060511
- 773 0_
- $w MED00008733 $t Human genomics $x 1479-7364 $g Roč. 18, č. 1 (2024), s. 83
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39030589 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110653 $b ABA008
- 999 __
- $a ok $b bmc $g 2202128 $s 1231682
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 18 $c 1 $d 83 $e 20240719 $i 1479-7364 $m Human genomics $n Hum Genomics $x MED00008733
- GRA __
- $a FNPl 00669806 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a 23-05609S $p Grantová Agentura České Republiky
- GRA __
- $a NV19-08-00113 $p Agentura Pro Zdravotnický Výzkum České Republiky
- LZP __
- $a Pubmed-20241015